archive-au.com » AU » C » CSL.COM.AU

Total: 502

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • News Archive
    sale of its JRH Biosciences Division JRH to Sigma Aldrich Corporation for US 370m cash subject to normal closing adjustments CSL s Managing Director Dr Brian McNamee said JRH is now positioned to move into its next stage of development and we hope that Sigma Aldrich can build on the strategic value that JRH brings to its cell culture reagent business Dr McNamee added that he wished the people at

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1196562810554/prdetail.htm (2014-01-05)
    Open archived version from archive


  • News Archive
    market environment and in light of our strong cash flows from operations our low net debt levels and various corporate initiatives we consider it appropriate to undertake a capital management program I m pleased to announce that the company proposes to conduct an on market share buyback of up to 10 million shares representing approximately 5 of issued capital Our preference is to maintain an efficient balance sheet Strong cashflows cash on hand and undrawn bank facilities give us the ability to fund the buyback while retaining the capacity to finance our research and development needs invest in our existing businesses and pursue strategic growth opportunities that may arise In line with the buyback initiative we are suspending the company s Dividend Reinvestment Plan Dr McNamee said BUSINESS REVIEW CSL Limited s operating results for the six months ended 31 December 2004 reflects the positive impact of the inclusion of six months trading by ZLB Behring Aventis Behring was acquired on 31 March 2004 and is currently in the final stages of integration with CSL s existing business ZLB to form ZLB Behring with 88 of integration milestones having now been achieved Financial benefit from the integration of the Commercial Operations and duplication of head office functions of ZLB Inc and Aventis Behring have been realised Similarly financial benefit from the rationalisation of Research and Development will increasingly be realised in the second half of fiscal 2005 Synergy benefits are now starting to build up in inventory manufactured under the new lower output manufacturing plan in the restructured business The majority of this financial benefit will flow in fiscal 2006 and beyond as the inventory is sold Registration in Bern of Kankakee s fractions II III has been achieved and transfer of this paste between the manufacturing facilities in the US and Switzerland has commenced This key element in delivering yield benefits for the company has been accomplished ahead of plan Remaining integration tasks will revert to site managers in April of this year when the integration office is closed The inventory acquired with Aventis Behring has been successfully managed down by US 160 million and converted to cash The Human Health business result includes some recent increases in the average sale price of IVIG in the USA and the realisation of 95 8m in discounted inventory US 70 5 million that was acquired as part of the Aventis Behring acquisition A new Plasma Products Agreement with the Australian National Blood Authority was signed in December 2004 providing for the supply of a broad range of plasma therapeutics from the Group s Broadmeadows production facility for a period of five years An agreement has been reached with Bayer HealthCare Australia for the exclusive distribution rights for Kogenate FS in Australia for an initial period of five years Kogenate FS is a leading recombinant factor VIII and as the market becomes available enables CSL Bioplasma to offer an expanded range of products to people living with Haemophilia A In December 2004

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1196562810602/prdetail.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    Australians living with Haemophilia A Melbourne Australia 17 02 2005 CSL Limited Australia s national fractionator of plasma therapeutics since 1952 and Bayer HealthCare Australia today announced an agreement with an initial 5 year term granting CSL Limited s Bioplasma Division exclusive distribution rights to KOGENATE FS in Australia KOGENATE FS is a leading recombinant Factor VIII used in the treatment of Haemophilia A and manufactured using advanced recombinant DNA technology With the addition of KOGENATE FS CSL Bioplasma is able to offer an expanded range of trusted products to people living with Haemophilia A CSL Bioplasma will now provide KOGENATE FS a leading recombinant Factor VIII in addition to BIOSTATE a world class plasma derived Factor VIII fractionated from plasma donated by Australians Mr Paul Bordonaro General Manager of CSL s Bioplasma Division said today This collaboration will combine the innovation of Bayer HealthCare with CSL Bioplasma s comprehensive distribution and on the ground customer support capability in Australia and ensure Australians have long term access to KOGENATE FS said Mr Bordonaro Australia Bayer HealthCare Managing Director Mr Derrill Palidwar commented This collaboration has been designed to ensure there will be product choice available for Australians The combined expertise

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1196562810679/prdetail.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    Archive CSL Limited and Merck Co Inc Enter Into Cross License and Settlement Arrangement with GlaxoSmithKline For HPV Vaccine Patents CSL Limited and Merck Co Inc Enter Into Cross License and Settlement Arrangement with GlaxoSmithKline For HPV Vaccine Patents Melbourne Australia 03 02 2005 CSL today announced a cross license and settlement arrangement between CSL Merck Co Inc Merck and GlaxoSmithKline GSK regarding certain patents related to the human papillomavirus HPV vaccine In 1995 CSL entered into an exclusive License Agreement with Merck for certain patents and know how related to HPV which had been previously licensed by CSL from the University of Queensland as a result of a research collaboration undertaken between them This collaboration formed the basis for the development by Merck of an investigational HPV vaccine candidate which is currently in Phase III clinical trials The financial terms between CSL and Merck are unchanged by the Agreement announced today However depending upon the outcome of certain US patent proceedings CSL would receive royalties from Merck for an extended period Under the arrangement announced today and in addition to milestones and royalties payable by Merck CSL will also receive from GSK separately negotiated milestones and royalties related to

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1196562810710/prdetail.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    2004 CSL s Managing Director Dr Brian McNamee said JRH is poised to move into its next stage of development To ensure JRH s continuing success and maximise its value to CSL we have decided to divest the business The sale unlocks significant value for CSL shareholders and provides an outstanding return on CSL s investment in JRH which was purchased in 1994 for US 20m when operating at a loss he said The Board is delighted that Sigma Aldrich has recognised the strategic value of JRH s expertise in the science associated with cell culture and sera and the quality of its operations and people Dr McNamee said JRH is a global market leader in developing manufacturing and marketing cell culture and serum products and services that are used in manufacturing vaccines biopharmaceuticals and gene therapy products The business employs approximately 400 people and has operations located at Lenexa Kansas USA Denver Pennsylvania USA Caseyville Illinois USA Andover United Kingdom and Brooklyn Victoria Australia Dr McNamee said The sale of JRH is another step in reshaping CSL as a leading human biopharmaceutical company with a focus on innovation in medical therapies In March of last year CSL purchased Aventis

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1196562810761/prdetail.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    Newsroom News Archive Plasma Products Agreement Signed Plasma Products Agreement Signed Melbourne Australia 23 12 2004 CSL Limited announced today that it has signed an agreement with the National Blood Authority acting on behalf of both State and Commonwealth Governments to continue to provide the Australian community with safe secure and affordable plasma therapeutic products CSL welcomes the opportunity to continue to provide life saving plasma therapeutics to Australians living with a variety of serious medical conditions the Managing Director and Chief Executive Officer of CSL Limited Dr Brian McNamee said today Under the new Plasma Products Agreement CSL will supply a broad range of plasma therapeutics manufactured exclusively at its Broadmeadows Victoria production facility from plasma provided by the Australian Red Cross Blood Service In addition under the new Agreement CSL will provide a comprehensive range of services to the National Blood Authority and medical providers involved in specialised therapeutic areas The Agreement also supports the important long standing collaboration between CSL and the Australian Red Cross Blood Service This collaboration ensures that Australians will continue to have secure safe and prompt access to a comprehensive range of plasma derived medical treatments The Plasma Products Agreement will commence on

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1196562811483/prdetail.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    months of trading of the combined ZLB Behring Research Development expenditure of 101 2 million up 11 reaffirming CSL s commitment to R D Net operating cashflow of 207 million up 79 on the previous year Final dividend of 26 cents fully franked bringing the full year dividend to 38 cents fully franked The purchase of Aventis Behring at a discount to fair value of US 296 million which has been merged with ZLB to form ZLB Behring Net proceeds from the sale of the Animal Health business of 162 million against a book value of 60 million resulting in a net profit after tax of 75 million Dr McNamee CSL s Managing Director said This has been a transformation year for CSL firstly with the landmark acquisition of Aventis Behring whose acquisition has considerably strengthened our global plasma therapeutics business and secondly with the sale of our Animal Health business The plasma industry has experienced welcome structural change on a global scale and we have been able to position CSL strongly for substantial profitable growth INTEGRATION OF ZLB BEHRING The Company advised that integration of ZLB Behring had progressed well with the following milestones being achieved Restructuring of Headquarters in King of Prussia was largely complete The Glendale office has been closed and the Vienna site was closing Restructuring of the Global Commercial Operations and the Plasma Collection Businesses were well advanced The restructuring of Kankakee was completed The Company confirmed that although more than 60 of identified integration milestones had been completed Marburg restructuring and IT systems integration were still to be finalised while transfer of intermediates between Kankakee and Bern required validation FDA submission and approval OUTLOOK Commenting on the outlook for CSL Dr McNamee said The plasma therapeutics industry is rationalising with the market moving to

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1196562811577/prdetail.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    Business Development Investors Corporate Responsibility Careers Newsroom News Archive Subscribe to News Alert Search News by Date Contact CSL Home Newsroom News Archive Dividend Reinvestment Plan Dividend Reinvestment Plan Melbourne Australia 26 08 2004 Dividend Reinvestment Plan Final Dividend Fiscal 2004 The price for CSL shares acquired under the Dividend Reinvestment Plan was calculated based on a 2 5 discount to the volume weighted average price of CSL shares traded

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1196562811547/prdetail.htm (2014-01-05)
    Open archived version from archive